High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo

Journal of the International AIDS Society

Volumn 19, Issue 1, 2016, Pages

  Salou, Mounerou ^a   Dagnra, Anoumou Y ^a   Butel, Christelle ^b   Vidal, Nicole ^b   Serrano, Laetitia ^b   Takassi, Elom ^c   Konou, Abla A ^a   Houndenou, Spero ^d   Dapam, Nina ^d   Singo Tokofaï, Assetina ^d   Pitche, Palokinam ^e   Atakouma, Yao ^a,c   Prince David, Mireille ^a   Delaporte, Eric ^b   Peeters, Martine ^b  

^a UNIVERSITY OF LOMÉ   (Togo)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c UNIVERSITÉ DE LOMÉ   (Togo)

^d AssociationEspoir pour Demain ^*  (Togo)

^e Faculté des Sciences de la Santé   (Togo)

Author keywords

Africa; Antiretroviral treatment; Children; Drug resistance; HIV; Togo; Virological failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RILPIVIRINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CHILD; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TOGO; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VERTICAL TRANSMISSION; VIROLOGY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; TOGO; VIRAL LOAD;

EID: 84973663749     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.19.1.20683     Document Type: Article

References (29)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact sheet: 2014 statistics. [cited 2015 Sep 4]. Available from: http://www.unaids.org/sites/ default/files/media-asset/20150714-FS-MDG6-Report-en.pdf
2. Joint United Nations Programme on HIV/AIDS (UNAIDS). '15 by 15' a global target achieved. [cited 2014 Sep 4]. Available from: http://www.unaids.org/ sites/default/files/media-asset/UNAIDS-15by15-en.pdf
3. Newell M-L, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:123643.
4. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, Nalugoda F, et al. Mortality in HIV-infected and uninfected children of HIVinfected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr. 2006;41(4):5048.
5. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011;377:15807.
6. Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, et al. Genotypic human immunodeficiency virus type 1 drug résistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. Pediatr Infect Dis J. 2005;24:10726.
7. Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, et al. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy. Pediatr Infect Dis J. 2006;25:104956.
8. Lwembe R, Ochieng W, Panikulam A, Mongoina CO, Palakudy T, Koizumi Y, et al. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol. 2007; 79:86572.
9. Adjé-Touré C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou O, et al. Virologic and immunologic response to antiretroviral therapy andpredictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire. AIDS Res Hum Retroviruses. 2008;24:9117.
10. Gody JC, Charpentier C, Mbitikon O, Si-Mohamed O. High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr. 2008;49:5669.
11. Vaz P, Chaix ML, Jani I, Macassa E, Bila D, Vubil A, et al. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J. 2009;28:e2837.
12. Germanaud D, Derache A, Traore M, Madec Y, Toure S, Dicko F, et al. Level of viral load and antiretroviral resistance after 6 months of non nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother. 2010;65:11824.
13. Bratholm C, Johannessen A, Naman E, Gundersen SG, Kivuyo SL, Holberg-Petersen M, et al. Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital. J Antimicrob Chemother. 2010;65:19962000.
14. Ruel TD, Kamya MR, Li P, Pasutti W, Charlebois ED, Liegler T, et al. Early failure and the development of antiretroviral drug resistance mutations in HIVinfected Ugandan children. J Acquir Immune Defic Syndr. 2011;56:4450.
15. Kebe K, Thiam M, Diagne -Gueye NR, Diop-Ndiaye H, Dia A, Signate- Sy H, et al. High rate of antiretroviral drug resistance mutations in HIH type 1-infected Senegalese children in virological failure on first line treatment according to world health organization guidelines. AIDS Res Hum Retroviruses. 2013;29:2429.
16. Joint United Nations Programme on HIV/AIDS (UNAIDS). [cited 2015Sep 4]. Available from: http://www.unaids.org/fr/regionscountries/countries/ togo
17. Konou A, Dagnra A, Vidal N, Salou M, Adam Z, Singo-Tokofai A, et al. Alarming rates of virological failure and drug resistance in patients on longterm antiretroviral treatment in routine HIV clinics in Togo. AIDS. 2015;29: 252730.
18. Salou M, Butel C, Konou A, Ekouevi D, Vidan N, Dossim S, et al. High rates of drug resistance among newly diagnosed HIV-infected children in the national prevention of mother-to-child transmission program in Togo. Pediatr Infect Dis J 2016. (in press).
19. Monleau M, Montavon C, Laurent C, Segondy M, Montes B, Delaporte E, et al. Evaluation of different RNA extraction methods and storage conditions ofdried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol. 2009;47:110718.
20. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59:30721.
21. World Health Organization (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneve, Suisse: WHO.
22. Pillay S, Bland MR, Lessells RJ, Manasa J, de Oliveira T, Danaviah S. Drug resistance in children at Virological failure in a rural KwaZulu-Natal, South Africa, cohort. AIDS Res Ther. 2014;11:3.
23. Barry O, Powell J, Renner L, Bonney EY, Prin M, Ampofo W, et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. BMC Infect Dis. 2013;13:476.
24. Orell C, Levison J, Ciaranello A, Bekker LG, Kuritzkes DR, Freedberg KA, et al. Resistance in pediatric patients experiencing virologic failure with first and second line antiretroviral therapy. Pediatr Infect Dis J. 2013;32(6):6447.
25. Mutwa PR, Boer KR, Rusine J, Muganga N, Tuyishimire D, Schuurman R, et al. Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1 infected children in Rwanda. Pediatr Infect Dis J. 2014;33:639.
26. Abrams EJ, Weedon J, Steketee RW, Lambert G, Bamji M, Brown T, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City perinatal HIV transmission Collaborative study Group. J Infect Dis. 1998;178:1018.
27. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:18793.
28. World Health Organization (2014). Health for the world's adolescents: a second chance in the second decade. Geneva: World Health Organization.
29. Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et al. Special contribution 2014 Update of the drug resistance mutations in HIV-1.Top Antivir Med. 2014;22:64250.